Another Genzyme Rival Advancing

Xconomy Boston — 

The corporate parent of Cambridge, MA-based Shire Human Genetic Therapies said today that it has wrapped up the submission of its FDA application for approval of velaglucerase alfa, an enzyme-replacement therapy for patients with Type 1 Gaucher’s disease. The company still needs FDA approval before it begins U.S. sales of the treatment. Cambridge-based Genzyme (NASDAQ:GENZ) sells the market-leading drug for Gaucher’s disease, imiglucerase (Cerezyme). Shire Human Genetic Therapies, which is developing velaglucerase alfa, is a unit of the Irish drug firm Shire (LSE:SHP).